The treatment of neuronally differentiated SH-SY5Y-APP cells with trans-crocin 4 showed a significant decrease in BACE1, which represents a validated target for AD therapy due to its distinctive role in its pathogenesis (Jonsson et al., 2012). Here, APP is linked to Alzheimer disease.